Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

NCT05142228 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low enrollment rate

Conditions

Trigeminal Neuropathy

Interventions

DRUG: Erenumab-Aooe
OTHER: Placebo

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]